North America Embolotherapy Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Product (Embolic Agent and Support Device), Disease Indication (Cancer, Peripheral Vascular Disease, Neurological Disease, Urological and Nephrological Disord

North America Embolotherapy Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Product (Embolic Agent and Support Device), Disease Indication (Cancer, Peripheral Vascular Disease, Neurological Disease, Urological and Nephrological Disorder, Gastrointestinal Disorder, and Other), Procedure [Transcatheter Arterial Embolization (TAE), Transcatheter Arterial Radioembolization (TARE)/Selective Internal Radiation Therapy (SIRT), and Transarterial Chemoembolization (TACE)], and End User (Hospital & Clinic, Ambulatory Surgery Center, and Other End User)

The embolotherapy market in North America is expected to grow from US$ 1,354.02 million in 2022 to US$ 2,245.73 million by 2028. It is estimated to grow at a CAGR of 8.8% from 2022 to 2028.

Rising Preference for Minimally Invasive Procedures Drives Growth of Embolotherapy Market in North America Patients increasingly prefer minimally invasive surgeries due to their various advantages such as low postoperative pain, less postoperative complications, short hospital stays, and fast recovery times. Trans Arterial Chemo Embolization (TACE) is a minimally invasive procedure that is typically used to treat hepatocellular carcinoma. TACE is used for patients suffering from asymptomatic and unresectable liver cancer. TACE can be used to diminish the size of the tumor and make the patient eligible for liver transplantation. It is considered an evolution from a formerly applied technique called Trans-catheter Arterial Embolization (TAE). Bleeding is a common issue in cancer patients, related to local tumor invasion, tumor angiogenesis, systemic effects of cancer, and anti-cancer treatments. TACE involves a two-step process—selective arterial occlusion restricts the blood supply to the tumor, which causes ischemic tumor necrosis, and regional chemotherapy helps the drug remain in the area for a prolonged period, which starts causing the therapeutic effects. Prostatic artery embolization (PAE) is also a minimally invasive therapy implemented as an elective outpatient technique for lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH). The number of patients treated with PAE has grown in recent years. Thus, the increasing preference for minimally invasive procedures is fueling the embolotherapy market growth in North America.

Market Overview



The North America embolotherapy market is segmented into the US, Canada, and Mexico. The US held the largest share of the market in 2021, owing to the growing prevalence of hepatocellular cancer and liver cancer coupled with the increasing focus of the major manufacturers on technological advancements. Furthermore, the advanced healthcare sector of the region, the prevalence of sophisticated technological healthcare facilities. The embolotherapy market in the region is anticipated to grow significantly in the coming years owing to the rising cases of brain aneurysms. According to the Brain Aneurysm Foundation’s report, ~6 million people have unruptured brain aneurysms in the US. Also, the annual rate of rupture is nearly 8–10 per 100,000 people; ~30,000 people in the country suffer from a brain aneurysm rupture. In addition, about 4 out of 7 people who recover from a ruptured brain aneurysm are likely to suffer from the disabilities. This neurological disorder generally affects people who are in the age group of 35–60 years. However, the brain aneurysm can also be seen in children, and women in the country suffer more than men.

North America Embolotherapy Market Revenue and Forecast to 2028 (US$ Million)

North America Embolotherapy Market Segmentation

The North America embolotherapy market is segmented on the basis of product, disease indication, procedure, end user, and country.

Based on product, the North America embolotherapy market is bifurcated into embolic agents and support devices. The embolic agents segment held a larger market share in 2022. Based on disease indication, the North America embolotherapy market is segmented into cancer, neurological diseases, urological and nephrological disorders, peripheral vascular diseases, gastrointestinal disorders, and others. The cancer segment held the largest market share in 2022. Based on procedure, the North America embolotherapy market is segmented into transcatheter arterial embolization (TAE), transcatheter arterial radioembolization/selective internal radiation therapy, and transarterial chemoembolization (TACE). The transcatheter arterial embolization (TAE) segment held the largest market share in 2022. Based on end user, the North America embolotherapy market is segmented into hospitals and clinics, ambulatory surgical centers, and other end users. The hospitals and clinics segment held the largest market share in 2022. Based on country, the North America embolotherapy market is segmented into the US, Canada, and Mexico. The US dominated the market in 2022. Abbott Laboratories, Boston Scientific Corporation, Cook Medical LLC, Johnson & Johnson, Medtronic, Acandis GmbH, Balt USA LLC, Stryker Corporation, Guerbet LLC, and Terumo Corporation are among the leading companies operating in the embolotherapy market in North America.

Reasons to Buy

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the North America embolotherapy market.
Highlights key business priorities in order to assist companies to realign their business strategies
The key findings and recommendations highlight crucial progressive industry trends in the North America embolotherapy market, thereby allowing players across the value chain to develop effective long-term strategies
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
Scrutinize in-depth North America market trends and outlook coupled with the factors driving the embolotherapy market, as well as those hindering it
Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution